BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990-2995. [PMID: 19724269 DOI: 10.1038/ajg.2009.453] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
2 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
3 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tanida S, Ozeki K, Kanno T, Katano T, Sugimura N, Nishie H, Iwasaki H, Tanaka M, Shimura T, Kubota E, Kataoka H. Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res 2021;13:510-4. [PMID: 34925662 DOI: 10.14740/jocmr4625] [Reference Citation Analysis]
5 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Endo Y, Yonekawa M, Kukita K, Katagiri M, Matsumoto T, Kawasaki K, Yanai S, Kato S, Kani K, Ogawa T, Kitamura K, Hasegawa I, Inoue Y, Doi T, Higuchi K, Kawakami K, Kakimoto K, Nakamura H. Novel adsorptive type apheresis device Immunopure for ulcerative colitis from clinical perspectives based on clinical trials: Japan and Europe. Ther Apher Dial 2021;25:432-6. [PMID: 33885215 DOI: 10.1111/1744-9987.13661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 45.0] [Reference Citation Analysis]
10 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mizutani Y, Fujii K, Kawamura M, Inoue M, Mizutani YH, Matsuyama K, Doi T, Nagaya S, Seishima M. Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis. J Dermatol 2020;47:1326-9. [PMID: 32860246 DOI: 10.1111/1346-8138.15569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res 2020;12:36-40. [PMID: 32010420 DOI: 10.14740/jocmr4037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Fukuchi T, Koga H, Kaichi S, Ishikawa A, Horita T, Araki R, Yokota A, Namba Y, Kyo M, Eguchi T, Shimazu K. Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis Is Suitable for Elderly Patients With Active Ulcerative Colitis Taking no Corticosteroids or Biologics. Ther Apher Dial. 2019;23:224-232. [PMID: 31025824 DOI: 10.1111/1744-9987.12819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rodríguez-Lago I, Sempere L, Gutiérrez A, Núñez A, Leo Carnerero E, Hinojosa E, Mora M, Cañete F, Mañosa M, Herrera C, Beltrán B, Forés A, Arjona D, Barreiro-de Acosta M, Khorrami S, Aguirre U, Ginard D, Cabriada JL. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol 2019;54:459-64. [PMID: 30982369 DOI: 10.1080/00365521.2019.1600715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
20 Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
21 Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Tanida S, Mizoshita T, Ozeki K, Katano T, Tanaka M, Nishie H, Shimura T, Okamoto Y, Kubota E, Kataoka H, Joh T. Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. Ther Apher Dial. 2018;22:295-300. [PMID: 29790276 DOI: 10.1111/1744-9987.12697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
23 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 214] [Article Influence: 63.0] [Reference Citation Analysis]
24 Sawada K. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease. Transfus Apher Sci 2017;56:689-97. [PMID: 28986009 DOI: 10.1016/j.transci.2017.08.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Shimazu K, Fukuchi T, Kim I, Noguchi Y, Iwata M, Koyama S, Ubukata S, Tanaka A. Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. Ther Apher Dial. 2016;20:383-389. [PMID: 27523079 DOI: 10.1111/1744-9987.12470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
26 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K, Okubo Y, Yamaguchi Y, Kambara T, Mabuchi T, Suga Y, Morita A, Yamanishi K, Tsuruta D, Itoh K, Yamaji K, Ikeda S. Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics. J Dermatol 2017;44:1353-9. [DOI: 10.1111/1346-8138.13975] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
28 Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol. 2017;11:749-758. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Watanabe Y, Kamimura K, Iwasaki T, Abe H, Takahashi S, Mizuno KI, Takeuchi M, Eino A, Narita I, Terai S. Case of severe alcoholic hepatitis treated with granulocytapheresis. World J Clin Cases 2016; 4(11): 369-374 [PMID: 27900326 DOI: 10.12998/wjcc.v4.i11.369] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 2015;15:163. [PMID: 26585569 DOI: 10.1186/s12876-015-0390-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
33 Tanida S, Mizoshita T, Nishie H, Ozeki K, Katano T, Kubota E, Kataoka H, Kamiya T, Joh T. Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res. 2015;7:884-889. [PMID: 26491502 DOI: 10.14740/jocmr2333w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
34 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
35 Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
36 Yuksel M, Saygili F, Coskun O, Suna N, Kaplan M, Kuzu UB, Kilic ZMY, Ozin YO, Kayacetin E. Treatment of Crohn’s disease and familial Mediterranean fever by leukopheresis: Single shot for two targets. World J Gastroenterol 2015; 21(13): 4078-4081 [PMID: 25852296 DOI: 10.3748/wjg.v21.i13.4078] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Yokoyama Y, Watanabe K, Ito H, Nishishita M, Sawada K, Okuyama Y, Okazaki K, Fujii H, Nakase H, Masuda T, Fukunaga K, Andoh A, Nakamura S. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17:680-688. [PMID: 25804800 DOI: 10.1016/j.jcyt.2015.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
38 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
39 Fukuchi T, Nakase H, Ubukata S, Matsuura M, Yoshino T, Toyonaga T, Shimazu K, Koga H, Yamashita H, Ito D. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease. BMC Gastroenterol. 2013;13:124. [PMID: 25015328 DOI: 10.1186/1471-230x-14-124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
40 Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M. Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma. Inflamm Res 2014;63:789-96. [PMID: 25001341 DOI: 10.1007/s00011-014-0753-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Schultheiß C, Weischenberg R, Herrmann A, Haller B, Schmid RM, Reindl W, Huber W. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artif Organs 2015;39:187-92. [PMID: 24981894 DOI: 10.1111/aor.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Yokoyama Y, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis. 2014;8:981-991. [PMID: 24556083 DOI: 10.1016/j.crohns.2014.01.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
43 Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis. 2014;46:219-226. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
44 Nagase K, Fukuanga K, Yokoyama Y, Kamikozuru K, Miwa H, Nakamura S. Questionnaire Based Assessment of Patients' Acceptability of Leukocytapheresis for the Treatment of Inflammatory Bowel Disease: Patients' Acceptability of Leukocytapheresis. Ther Apher Dial 2013;17:490-7. [DOI: 10.1111/1744-9987.12115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
46 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol 2013;2013:304894. [PMID: 23691335 DOI: 10.1155/2013/304894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
47 Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
48 Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
49 Takahashi H, Sugawara K, Sugimura M, Iwabuchi M, Mano Y, Ukai K, Tadokoro K. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013;288:341-347. [PMID: 23404436 DOI: 10.1007/s00404-013-2748-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
50 Winters JL. Randomized controlled trials in therapeutic apheresis: Randomized Trials in Apheresis. J Clin Apheresis 2013;28:48-55. [DOI: 10.1002/jca.21263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
51 Fukuchi T, Nakase H, Matsuura M, Yoshino T, Toyonaga T, Ohmori K, Ubukata S, Ueda A, Eguchi T, Yamashita H. Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohns Colitis. 2013;7:803-811. [PMID: 23352104 DOI: 10.1016/j.crohns.2012.12.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
52 Ikeda S, Takahashi H, Suga Y, Eto H, Etoh T, Okuma K, Takahashi K, Kanbara T, Seishima M, Morita A, Imai Y, Kanekura T. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013;68:609-17. [PMID: 23332516 DOI: 10.1016/j.jaad.2012.09.037] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 7.6] [Reference Citation Analysis]
53 Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
54 Ozeki K, Tanida S, Mizoshita T, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn’s Disease. Case Rep Gastroenterol. 2012;6:765-771. [PMID: 23341799 DOI: 10.1159/000346312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
55 Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433. [PMID: 23170145 DOI: 10.5009/gnl.2012.6.4.427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
56 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol. 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
58 Mizoshita T, Tanida S, Kusumoto S, Ozeki K, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol 2012;5:302-6. [PMID: 26182398 DOI: 10.1007/s12328-012-0314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis. 2013;7:e49-e54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
60 Sakuraba A, Sato T, Morohoshi Y, Matsuoka K, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study. Ther Apher Dial. 2012;16:213-218. [PMID: 22607563 DOI: 10.1111/j.1744-9987.2012.01064.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
61 Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogawa T, Matsuda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis. 2012;6:787-791. [PMID: 22386738 DOI: 10.1016/j.crohns.2012.02.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
62 Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
63 Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Chiba T, Endo M, Matsushita S, Sasaki M, Chida S, Toya Y, Kasugai S, Matsuda N, Orikasa S, Abiko Y, Kudara N, Oana S, Endo M, Suzuki K. Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive Apheresis. Case Rep Gastroenterol 2011;5:667-71. [PMID: 22220142 DOI: 10.1159/000335316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
65 Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol. 2012;47:359-365. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
66 Fukunaga K, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis. J Clin Apheresis 2011;26:326-31. [DOI: 10.1002/jca.20314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Incà R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011;26:332-7. [PMID: 22072543 DOI: 10.1002/jca.20315] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
68 Abe T, Kato K, Fujioka T, Akizawa T. The blood compatibilities of blood purification membranes and other materials developed in Japan. Int J Biomater 2011;2011:375390. [PMID: 21969830 DOI: 10.1155/2011/375390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol. 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
70 Nagase K, Fukunaga K, Kashiwamura S, Kono T, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Miwa H, Matsumoto T. Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease: Immunoregulatory Effects of GMA in CD. Therapeutic Apheresis and Dialysis 2011;15:367-73. [DOI: 10.1111/j.1744-9987.2011.00970.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
71 Kikuyama R, Fukunaga K, Kawai M, Yokoyama Y, Kamikozuru K, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kato K, Kono T, Nogami K, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Relevance of the Processed Blood Volume per Granulocyte and Monocyte Apheresis Session to its Clinical Efficacy in Patients With Ulcerative Colitis: Bodyweight Oriented GMA in UC Patients. Therapeutic Apheresis and Dialysis 2011;15:360-6. [DOI: 10.1111/j.1744-9987.2011.00968.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Fukuchi T, Nakase H, Ito D, Yamashita H, Matsuura M, Nagatani Y, Koga H, Senda K, Eguchi T, Ubukata S, Kawaguchi S, Ueda A, Tanaka T, Ohashi R, Otzuka M, Ashida K. Rapid induction of mucosal healing by intensive granulocyte and monocyte adsorptive aphaeresis in active ulcerative colitis patients without concomitant corticosteroid therapy: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;34:583-5. [DOI: 10.1111/j.1365-2036.2011.04768.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
73 Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011;46:1003-9. [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
74 Iizuka M, Sagara S, Etou T. Efficacy of long-interval cytapheresis on steroid-dependent refractory ulcerative colitis. Inflamm Bowel Dis 2011;17:E119-20. [PMID: 21674727 DOI: 10.1002/ibd.21786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Mizushima T, Tanida S, Mizoshita T, Hirata Y, Murakami K, Shimura T, Kataoka H, Kamiya T, Joh T. A complicated case of tacrolimus-induced rapid remission after cesarean section in the early third trimester for refractory severe ulcerative colitis flaring in the initial period of gestation. Case Rep Gastroenterol 2011;5:144-51. [PMID: 21552436 DOI: 10.1159/000326938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
76 Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis. 2011;26:999-1007. [PMID: 21476027 DOI: 10.1007/s00384-011-1193-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
77 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 158] [Article Influence: 12.5] [Reference Citation Analysis]
78 Vernia P, D’Ovidio V, Meo D. Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives. Transfus Apher Sci. 2010;43:227-229. [PMID: 20817610 DOI: 10.1016/j.transci.2010.07.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
79 Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905-1911. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
80 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
81 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
82 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
83 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8. [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
85 Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther. 2010;32:1297-1306. [PMID: 21050231 DOI: 10.1111/j.1365-2036.2010.04490.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
86 Franks I. Intensive GMA is more efficacious than weekly GMA for the treatment of ulcerative colitis. Nat Rev Gastroenterol Hepatol 2010;7:70-70. [DOI: 10.1038/nrgastro.2009.239] [Reference Citation Analysis]